Sign In
Buy PGEN
$3.81
-0.0500 (-1.30%)
At Close: Jun 03, 2026
Precigen Is Still A Buy After The Papzimeos Rally
06:51am, Tuesday, 25'th Nov 2025
Precigen (PGEN) remains a Buy after PAPZIMEOS' FDA approval and launch, with higher-than-expected pricing and broad label supporting robust revenue potential. A new Pharmakon credit facility extends P
Precigen (NASDAQ:PGEN) Stock Price Up 28.9% on Analyst Upgrade
03:46am, Saturday, 15'th Nov 2025
Precigen, Inc. (NASDAQ: PGEN - Get Free Report) traded up 28.9% during trading on Friday after HC Wainwright raised their price target on the stock from $8.50 to $9.00. HC Wainwright currently has a b
Precigen Sees Unusually Large Options Volume (NASDAQ:PGEN)
02:19am, Saturday, 15'th Nov 2025
Precigen, Inc. (NASDAQ: PGEN - Get Free Report) was the recipient of unusually large options trading activity on Friday. Traders acquired 10,952 call options on the stock. This represents an increase
Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript
10:51pm, Thursday, 13'th Nov 2025
Precigen, Inc. ( PGEN ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Steven Harasym - VP & Head of Investor Relations Helen Sabzevari - President, CEO & Director Phil Tenna
Precigen Reports Third Quarter 2025 Financial Results and Business Updates
04:05pm, Thursday, 13'th Nov 2025
PAPZIMEOS (zopapogene imadenovec-drba) received full approval by the FDA in August PAPZIMEOS launched with a broad label in the US as the first and only FDA-approved treatment for adults with RRP PAPZ
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
04:30pm, Thursday, 06'th Nov 2025
GERMANTOWN, Md. , Nov. 6, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of pa
Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares
12:33pm, Saturday, 01'st Nov 2025
Patient Capital increased its holding by 10.2 million shares, an estimated $28.78 million trade based on the average price for the quarter Transaction value represents 1.15% of reported 13F assets und
15 out of 18 complete responders (83%) demonstrate continued complete response with median follow-up of 36 months Reduction in surgeries compared to year prior to treatment with PAPZIMEOS was observed
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts
08:23am, Sunday, 07'th Sep 2025
Investors in search of stocks that can produce dramatic gains in a short time frame will want to turn their heads toward the healthcare sector. A handful of stocks in the space more than doubled in pr
Precigen Announces Up to $125 Million Non-Dilutive Financing
07:00am, Wednesday, 03'rd Sep 2025
$100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and o
Precigen, Inc. - Special Call
01:55pm, Tuesday, 02'nd Sep 2025
Precigen, Inc. - Special Call Company Participants Helen Sabzevari - President, CEO & Director Phil Tennant - Chief Commercial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwr
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
12:06pm, Monday, 25'th Aug 2025
Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
08:05am, Monday, 25'th Aug 2025
GERMANTOWN, Md. , Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of p
Undercovered Dozen: Precigen, ONEOK, Bitmine And More
10:43am, Friday, 22'nd Aug 2025
This week's Undercovered Dozen highlights 12 lesser-known stocks and ETFs with compelling investment theses and recent catalysts. Standouts include CGDV's market-beating performance, DIVO's retirement
Precigen price target raised to $8 from $6 at Citizens JMP
05:38am, Tuesday, 19'th Aug 2025
Citizens JMP raised the firm's price target on Precigen to $8 from $6 and keeps an Outperform rating on the shares. Precigen discussed the approval of PAPZIMEOS for the treatment of respiratory papill
